Previous 10 | Next 10 |
2023-05-24 17:16:00 ET Cyrus Arman, CytoDyn ( OTCQB:CYDY ) president, has taken a medical leave of absence. CFO Antonio Migliarese will assume Arman's responsibilities while he is out. Migliarese will be assisted by interim CMO Melissa Palmer and Salah Kivlighn, ...
Antonio Migliarese assumes interim President role Dr. Melissa Palmer appointed interim Chief Medical Officer Dr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington, May 24, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or th...
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Ar...
2023-03-28 10:52:34 ET Summary Former CytoDyn CEO Pourhassan's indictment is now public. Company is moving on with an entirely different management team. CytoDyn shares and its finances are both in the dumps. CytoDyn's future holds little promise for current shareholders. ...
Summary CYDY changed its CEO and made other major changes to the company. The company is trying to move away from initial indications to others that haven't failed yet. However, the entire leronlimab program is now in question. A few months ago, I wrote a bearish article...
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pac...
Nader Pourhassan, the former CEO of embattled biotech CytoDyn ( OTCQB:CYDY ), has been indicted by a federal court grand jury and accused of conspiracy to defraud investors in regards to the company's HIV candidate leronlimab. The stock is down ~12% in Tuesday afternoon ...
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will host a virtual R&D...
CytoDyn ( OTCQB:CYDY ) has voluntarily withdrawn a pending Biologics License Application for its HIV biologic leronlimab due to issues related to data collection and trial monitoring by its contract research organization . The company noted that it does not believe it can ...
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30 AM PT / 8:30 AM ET VANCOUVER, Washington, Oct. 28, 2022 (GLOBE NEWS...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering...